BEAM vs DSGN
BEAM: Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare genetic disorders. DSGN: A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene expression.
Side-by-side fundamentals
| Metric | BEAM | DSGN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $25.07 | $11.88 | |
| Market cap as of 2026-07-30 | $2.7B | $751M | |
| PEG as of 2026-07-30 | n/a | -0.49 | |
| Net margin as of 2026-07-30 | -39.7% | -3600.0% | BEAM higher |
| Operating margin as of 2026-07-30 | -226.6% | -3621.7% | BEAM higher |
| ROE as of 2026-07-30 | -5.9% | -33.1% | BEAM higher |
| ROA as of 2026-07-30 | -4.6% | -31.3% | BEAM higher |
| Debt / equity as of 2026-07-30 | 0.09 | 0.00 | DSGN lower |
| Revenue growth (YoY) as of 2026-07-30 | +158.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +31.9% | n/a | |
| Beta as of 2026-07-30 | 2.23 | 1.64 | |
| 1-year return as of 2026-07-27 close | +15.4% | +195.5% | DSGN higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.